v3.26.3
Commitments and Contingencies (Details Narrative) - USD ($)
9 Months Ended
Jun. 01, 2026
Dec. 15, 2024
May 01, 2021
Sep. 13, 2016
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Loss Contingencies [Line Items]              
Operating lease term 76 months   61 months        
Base rent $ 3,650   $ 3,783        
Operating lease yearly escalation percentage 3.00%   3.00%        
Operating lease right-of-use asset         $ 211,070   $ 23,214
Lease liability         $ 225,049    
Borrowing rate         8.00%    
Pharm Ala Biotech Holdings Inc. [Member]              
Loss Contingencies [Line Items]              
Commercialization milestone payments description         The Company is also obligated to make commercialization milestone payments totaling up to $73,333,333, consisting of (i) $10,000,000 upon achieving $333,333,333 in net sales, (ii) $30,000,000 upon achieving $1,000,000,000 in net sales, and (iii) $33,333,333 upon achieving $2,000,000,000 in net sales. Each milestone payment is payable only once upon achievement of the applicable milestone.    
Consulting Agreements [Member]              
Loss Contingencies [Line Items]              
Development and distribution fee   $ 2,300,000          
Related consulting expense         $ 573,425 $ 573,424  
Consulting Agreement [Member]              
Loss Contingencies [Line Items]              
Management and Service Fees, Rate   5.00%          
License Agreements [Member] | Aquanova AG [Member]              
Loss Contingencies [Line Items]              
License fee       $ 75,000      
Royalty percentage       1.25%      
Royalty Expense       $ 3,000,000.0      
License Agreements [Member] | Aquanova AG [Member] | Minimum [Member]              
Loss Contingencies [Line Items]              
Other Commitment       200,000      
License Agreements [Member] | Aquanova AG [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Other Commitment       $ 600,000      
Licensing and Royalty Agreements [Member]              
Loss Contingencies [Line Items]              
Royalty percentage       5.00%      
Development milestone payments description         Pursuant to the Strategic Asset License Agreement with PharmAla, the Company is obligated to make development milestone payments totaling up to $23,333,333, consisting of (i) $3,333,333 upon first dosing of the first patient in a Phase 3 clinical trial, payable 50% in cash and 50%, at PharmAla’s election, in cash or common stock, and (ii) $20,000,000 upon first FDA approval of a New Drug Application for a licensed product, payable in cash.    
Debt Forgiveness and Exchange Agreement [Member] | Aquanova AG [Member]              
Loss Contingencies [Line Items]              
Accrued license fees         $ 56,250   $ 0